Tecartus denied for missing prior authorization by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for tecartus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Requires Prior Authorization for Tecartus

Tecartus (brexucabtagene autoleucel) is a one-time CAR-T cell therapy for certain hematologic cancers. BCBS, like virtually all commercial insurers, requires prior authorization (PA) before this therapy is administered — both because of its cost and because its use involves specific clinical requirements. A denial for "prior authorization required" means the claim was submitted without a PA, or the PA request was incomplete or not reviewed before infusion. This is one of the most fixable denial types: the path forward is a properly documented PA request or a retrospective appeal.

## Federal Appeal Rights

• Internal appeal: Under ERISA §503 and ACA §2719, you have the right to a full-and-fair internal review of any adverse benefit determination. Submit within the deadline on your denial notice.
• External review: If the internal appeal is denied or BCBS does not respond within its required timeframe, you may escalate to an independent external reviewer. This right is available for up to approximately four months after a final internal denial under most ACA-compliant plans.
• Expedited review: When your oncologist documents that delay poses serious health risk, request expedited processing — the insurer must respond within 72 hours.

## What to Include in Your Appeal

1. Completed PA documentation: If PA was never submitted, submit it now as part of the retrospective review. Include all clinical records supporting medical necessity. 2. Diagnosis and staging records: Pathology, cytogenetics, imaging, or other documents confirming the specific diagnosis. 3. Prior treatment history with outcomes: A chronological list showing prior lines of therapy, dates, and documented responses, aligned to the requirements in the FDA-approved label for Tecartus. 4. Prescriber medical-necessity letter: A letter from the treating oncologist explaining why Tecartus is indicated, why the timing is medically necessary, and why alternatives are inadequate. 5. Treating center credentials: Confirmation that the administering center meets any REMS or certification requirements associated with CAR-T therapy.

## Criteria-Mapping Structure

For each item in BCBS's published Tecartus/CAR-T prior authorization criteria, document the matching chart evidence:

| PA Criterion (from BCBS policy) | Supporting Documentation | |---|---| | Confirmed diagnosis per label indication | Pathology report | | Number/type of prior therapies per label | Treatment summary | | ECOG/performance status requirement | Oncology note | | Certified treatment center | Center letter or REMS documentation |

## Next Step

Download BCBS's current Tecartus prior authorization criteria from their provider portal or member site. Cross-reference every listed requirement against your records before resubmitting. An oncology social worker or patient advocate at the treating CAR-T center can often assist with the PA submission process.